{
    "eid": "2-s2.0-85159758145",
    "title": "Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5\u221211 years",
    "cover-date": "2023-05-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Virology",
            "@code": "2406",
            "@abbrev": "IMMU"
        }
    ],
    "keywords": [
        "booster",
        "inactivated",
        "mRNA",
        "Omicron",
        "severe acute respiratory virus 2 (SARS-CoV-2)",
        "vaccine"
    ],
    "authors": [
        "Nasamon Wanlapakorn",
        "Sitthichai Kanokudom",
        "Harit Phowatthanasathian",
        "Jira Chansaenroj",
        "Nungruthai Suntronwong",
        "Suvichada Assawakosri",
        "Ritthideach Yorsaeng",
        "Pornjarim Nilyanimit",
        "Preeyaporn Vichaiwattana",
        "Sirapa Klinfueng",
        "Thanunrat Thongmee",
        "Ratchadawan Aeemjinda",
        "Nongkanok Khanarat",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Warangkana Chantima",
        "Pattarakul Pakchotanon",
        "Thaneeya Duangchinda",
        "Natthinee Sudhinaraset",
        "Yong Poovorawan"
    ],
    "citedby-count": 1,
    "ref-count": 27,
    "ref-list": [
        "Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age",
        "SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era",
        "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial",
        "Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial",
        "COVID-19 vaccine safety in children aged 5-11 years\u2014United States, November 3 to December 19, 2021",
        "Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals",
        "Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccine",
        "Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization",
        "Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand",
        "Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination",
        "Immunogenicity following two doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA COVID-19 vaccines against Delta and Omicron variants in prime immunized adults with two doses of the BBIBP-CorV vaccine",
        "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data",
        "Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study",
        "Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination",
        "Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile",
        "BNT162b2 protection against the Omicron variant in children and adolescents",
        "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials",
        "The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years\u2014United States, November 2021",
        "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant",
        "Heterologous prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among healthy Thai adolescents",
        "Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination",
        "Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60011947",
            "affilname": "Thailand National Center for Genetic Engineering and Biotechnology",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011947",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "126510119",
            "affilname": "FRS(T)",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/126510119",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology",
        "Second Century Fund",
        "King Chulalongkorn Memorial Hospital",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}